Skip to main content

Table 1 Baseline clinical features

From: Acute exacerbations of fibrosing interstitial lung disease associated with connective tissue diseases: a population-based study

 

n

All patients

AE-IPF group

AE-CTD-ILD group

p value

Clinical Characteristics

 Gender (M/F)

177

116/61

81/26

35/35

< 0.001

 Age (years old)

177

67.46 ± 9.72

68.52 ± 9.87

65.84 ± 9.33

0.073

 Smoking history (Y/N)

177

56/121

38/69

18/52

0.170

 Prior corticosteroids use (Y/N)

177

125/52

68/39

57/13

0.011

 Prior immunosuppressant use (Y/N)

177

39/138

3/104

36/34

< 0.001

 Prior NAC use (Y/N)

177

153/24

91/16

62/8

0.503

 Reduction or Discontinuation of corticosteroids before AE (Y/N)

177

57/120

34/73

23/47

0.880

 Fever (Y/N)

177

105/72

62/43

43/29

0.861

 WBC count (×109)

177

11.12 ± 4.55

11.26 ± 4.91

10.91 ± 3.97

0.619

 ESR (mm/h)

177

39 (0–120)

39 (0–120)

40 (0–101)

0.275

 CRP (mg/L)

177

50.2 (0.2–246)

47 (0.2–243.5))

56.05 (0.2–246)

0.603

 LDH (U/L)

177

439.26 ± 174.13

438.28 ± 158.32

440.76 ± 197.06

0.927

 ALB (g/L)

177

32.14 ± 3.48

32.88 ± 3.45

31.01 ± 3.23

< 0.001

 BNP (pg/ml)

125

94.30 (0–1130)

104 (5–828)

88.15 (0–1130)

0.869

 PaO2/FiO2 ratio

177

126 (34–357)

121 (45–246)

140.50 (34–357)

0.050

 D-dimer (mg/L)

153

1.84 (0.02–24.82)

1.46 (0.02–22.4)

2.06 (0.10–24.82)

0.023

 CT Score

177

8 (4–8)

8 (4–8)

8 (4–8)

0.772

 FVC (L)

105

2.02 (0.74–4.61)

2.05 (0.74–3.36)

1.86 (0.86–4.61)

0.886

 FVC % pred

105

63.22 ± 18.39

60.33 ± 17.32

66.18 ± 19.20

0.170

 TLC% pred

89

53.15 ± 12.81

48.80 ± 13.53

57.67 ± 10.45

0.012

 DLCO % pred

89

41.66 ± 15.59

38.66 ± 14.78

44.78 ± 16.09

0.163

 PAH (mmHg)

89

42 ± 9.848

41.97 ± 9.642

42.03 ± 10.222

0.980

 BMI (kg/m2)

105

24.44 (17.58–34.11)

24.44 (17.99–30.53)

24.52 (17.58–34.11)

0.836

 Anti-fibrotic therapy (Y/N)

3

3/176

3/104

0/70

0.279

Treatments after AE

 Mechanical Ventilation (MV, Y/N)

177

93/84

57/50

36/34

0.810

 Maximal dosage of methylprednisonle (mg/d)

177

240 (40–1000)

240 (40–1000)

240 (40–1000)

0.252

 Immunosuppressant (Y/N)

177

58/119

14/93

44/26

< 0.001

 Immunoglobulin (Y/N)

177

72/105

43/64

29/41

0.869

 Co-trimoxazole (Y/N)

177

99/78

57/50

42/28

0.378

 Caspofungin (Y/N)

177

38/139

16/91

22/48

0.009

  1. AE = acute exacerbation; IPF = idiopathic pulmonary fibrosis; fILD = fibrosing interstitial lung disease; CTDs = connective tissue diseases; NAC = N-acetylcysteine; WBC = white blood cell; ESR = erythrocyte sedimentation rate; CRP = C reactive protein; LDH = lactate dehydrogenase; ALB = albumin; BNP = B-type natriuretic peptide; PaO2/FiO2 = Oxygenation index; CT = Computed tomography; UIP = usual interstitial pneumonia; P-UIP = possible UIP; FVC = forced vital capacity; TLC = total lung capacity; DLCO = diffusing capacity of the lung for CO2; PAH = pulmonary arterial hypertension; BMI = body mass index; MV = mechanical ventilation
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us